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Tuberculous meningitis (TBM) is a frequent cause 
of meningitis in South Africa (SA) and has a dismal 
prognosis.[1] In a study from a Cape Town hospital, 
TBM accounted for more than half of adult meningitis 
cases over a 6-month period; at 6-month follow-up 
mortality was 48%.[1] HIV co-infection, particularly in patients with 
severe immunosuppression, increases the risk of disseminated forms 
of tuberculosis (TB), such as meningitis, and contributes significantly 
to the TBM burden in high HIV/TB settings. The diagnosis of 
TBM is often complicated and optimal management strategies are 
uncertain; such challenges are likely to contribute to poor outcome 
in affected patients.[2] 
Diagnosis
Early diagnosis and treatment initiation are crucial to improve 
outcome in TBM, as advanced disease, prolonged symptom duration 
and delayed treatment initiation are associated with increased 
mortality during hospitalisation, when the majority of deaths 
occur.[2] As discussed below, definitive microbiological tests for 
TBM are insensitive; therefore diagnosis and TB treatment initiation 
are usually based on a combination of suggestive clinical and 
cerebrospinal fluid (CSF) findings, evidence of TB outside the central 
nervous system (CNS), supportive features on brain imaging (if 
available) and exclusion of other common causes for meningitis.[3] 
Clinical findings 
TBM typically presents sub-acutely after an average of 5 - 30 days 
of neurological symptoms (e.g. headache, vomiting, neck pain/
stiffness, seizures, focal neurological signs and confusion)[3] – unlike 
bacterial meningitis, which usually presents more acutely, but similar 
to cryptococcal meningitis (CM). However, shorter (a few days) 
or longer (>1 month) duration of neurological symptoms is well 
described and does not exclude the diagnosis of TBM. Systemic 
symptoms of Mycobacterium tuberculosis infection, such as cough, 
night sweats and loss of weight, may be indicative of TB, but may also 
be present with other causes of meningitis. Untreated HIV infection 
frequently results in loss of weight.
Routine CSF features
The usual CSF findings in TBM include the combination of a clear 
appearance, lymphocyte-predominant pleocytosis (50 - 1 000 × 106/L), 
increased protein concentrations (0.5 - >2.5 g/L) and decreased glucose 
(CSF/blood ratio <0.5 or absolute value <2.2 mmol/L).[2] However, 
atypical routine CSF findings that may cause diagnostic uncertainty 
are well described, including a mildly elevated or normal white 
cell count, normal protein or glucose concentrations, neutrophil 
predominance, or completely normal CSF. Atypical findings occur 
more frequently in the context of HIV infection, and a normal 
CSF white cell count is particularly common with severe immune 
suppression (CD4+ count <50 cells/μL).[4] 
Features of TB elsewhere
A search for evidence of TB outside the CNS is crucial in the 
diagnostic work-up of suspected TBM. Chest radiography should be 
performed in all cases, as abnormalities suggestive of TB are seen in a 
large proportion (33 - 85%) of TBM patients.[4] Further investigations 
such as sputum examination (smear, culture and/or Xpert), lymph 
node fine-needle aspiration biopsy and abdominal ultrasound should 
be considered, depending on the clinical presentation. 
Brain imaging
The most common reason for brain imaging (usually computed 
tomography (CT)) in suspected TBM in SA is to rule out a 
contraindication to lumbar puncture (LP). Contrast-enhanced 
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brain imaging may additionally be useful in suspected TBM where 
diagnostic uncertainty exists. Typical imaging features, including 
hydrocephalus, basal meningeal enhancement, tuberculoma(s) and/
or infarcts, may provide supportive evidence for a diagnosis of 
TBM in such cases (Fig. 1). However, brain imaging may be 
completely normal, especially early during the course of the disease. 
Furthermore, several factors may complicate the interpretation 
of brain imaging results in HIV-infected patients. In particular, 
generalised cerebral atrophy is common in the context of HIV 
and could be confused with communicating hydrocephalus, and a 
tuberculoma has a similar radiological appearance to other causes 
of intracranial space-occupying lesions, such as toxoplasmosis, 
commonly seen in HIV-infected patients. 
Exclusion of other causes of 
meningitis
The most common differential diagnosis for TBM in SA, which 
predominantly affects HIV-infected patients, is CM.[1] CM cannot 
be distinguished from TBM by clinical or routine CSF findings 
and should be investigated by CSF India ink and/or cryptococcal 
antigen testing with or without fungal culture. CSF Gram staining 
and bacterial culture should be performed to exclude pyogenic 
bacterial meningitis. However, negative stain and culture results do 
not always exclude a diagnosis of bacterial meningitis, especially in 
patients partially treated with antibiotics before presentation, and 
a high index of suspicion should be maintained in such cases, as 
well as in those with a CSF neutrophil predominance. Meningitis 
due to non-opportunistic viruses (e.g. Enterovirus) that does 
not require specific treatment may mimic TBM. These viruses 
can be investigated in selected patients by CSF viral polymerase 
chain reaction (PCR). HIV itself is often associated with chronic 
CSF inflammation, including mildly increased lymphocyte counts 
(5 - 25 cells ×106/L) and protein concentrations (0.46 - 1 g/L). 
This emphasises the importance of considering CSF results in 
the context of clinical and other investigative findings. Patients in 
whom considerable doubt regarding the diagnosis exists, such as 
those with atypical presentations and mild CSF abnormalities, a 
watch-and-wait approach could be employed with an LP repeated, 
if necessary, a few days after the initial LP. A limited list of other 
infectious differential diagnoses of HIV-associated TBM and their 
investigation is presented in Table 1.
Definitive diagnostic methods
Detection of acid-fast bacilli in CSF by smear examination is a rapid, 
inexpensive method of confirming the diagnosis of TBM. However, 
studies from SA report extremely low diagnostic yields by this 
method.[5] Culture of M. tuberculosis from CSF is similarly an insensitive 
diagnostic test and as time to positivity is at least 2 weeks, it is too slow to 
be clinically relevant in guiding treatment initiation in TBM.[3] Measures 
shown to improve the sensitivity of these microbiological tests, which 
can easily be implemented in our setting, include analysing large 
volumes of CSF (≥6 mL is advised), and performing repeated LPs.[6,7] 
The Xpert MTB/RIF test (Xpert, Cepheid, Sunnyvale, CA, USA), 
a real-time PCR assay for M. tuberculosis that simultaneously detects 
rifampicin (RIF) resistance, is of potential value in the rapid diagnosis 
of TBM. In a study of TBM patients from Vietnam, the overall 
sensitivity of Xpert on CSF was 59.3% using clinical diagnosis as the 
reference standard, and the specificity was 99.5%.[8] In this study, 
the sensitivity of Xpert was significantly higher in HIV-infected 
compared with HIV-uninfected patients (sensitivity 78.8% v. 47.9%). 
In a predominantly HIV-infected SA TBM cohort study (87% of the 
204 participants were HIV-infected), the sensitivity and specificity 
of Xpert were 67% and 94%, respectively; this analysis included 
patients with definite TBM (CSF M. tuberculosis culture and/or 
Amplicor PCR positive), compared with patients with other causes 
of meningitis as controls.[9] Although the overall sensitivity decreased 
to 36% when probable TBM was included in the reference standard, 
using a larger volume (3 mL) of centrifuged CSF compared with 1 mL 
of neat CSF increased the sensitivity markedly from 26% to 65% in 
this analysis. 
Management
TB treatment
Similar to guidelines globally, current SA Department of Health (SA 
DoH) guidelines suggest RIF, isoniazid, ethambutol and pyrazinamide 
for 2 months, followed by RIF and isoniazid for a further 7 months as 
first-line treatment in adults with CNS TB. However, the principles 
of treating TBM are based on those developed for pulmonary TB and 
not informed by randomised controlled trials (RCTs) in TBM.[2] RIF 
is one of the backbone drugs in TBM treatment, but the evidence 
for the current recommended dose (10 mg/kg/day) is scant and may 
be too low. RIF has poor CSF penetration and TBM patients often 
present critically ill, vomit and receive drugs through a nasogastric 
tube. All these factors may further contribute to suboptimal CNS 
TB drug concentrations. Isoniazid and pyrazinamide have good 
CSF penetration and are therefore considered critical drugs in 
TBM treatment. However, the choice of the fourth drug during the 
initiation phase of TBM treatment is contentious.[2] Ethambutol 
crosses the meninges poorly at the recommended dose. Alternatives 
such as streptomycin and ethionamide are of limited use in TBM 
owing to poor CNS penetration, dose-limiting toxicity and intolerable 
Fig. 1. Computed tomogram of a patient with tuberculous meningitis 
(TBM). This contrast-enhanced axial image shows three typical features of 
TBM, including tuberculoma (white arrow), basal meningeal enhancement 
(red arrow) and hydrocephalus.
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gastrointestinal side-effects in adults. Fluoroquinolones such as 
levofloxacin and moxifloxacin have high bactericidal activity, are safe 
and well tolerated and have good CSF penetration; therefore they are 
attractive treatment options for TBM.
There is increasing interest in exploring alternative evidence-based 
treatment regimens for TBM. RCT findings suggest a mortality 
benefit from an ‘intensified’ treatment regimen early during TBM 
treatment.[10] This study investigated the safety and pharmacokinetic 
profiles of higher-than-normal dose, intravenous (IV) RIF and 
oral moxifloxacin in HIV-infected and -uninfected TBM patients. 
Although not powered to detect a mortality benefit, an improved 
outcome was observed in patients receiving IV RIF (~13  mg/kg/d) 
than in those on the oral standard dose during the initial 2 weeks of 
TB treatment. Patients who received IV RIF had a reduced mortality 
at 6-month follow-up (34%) compared with those who received oral 
RIF (65%). A further RCT assessing the use of higher doses of oral 
RIF (15 mg/kg/d) and oral levofloxacin in improving TBM outcome 
is currently ongoing in Vietnam (ISRCTN61649292). Results of this trial, 
which may lead to changes in treatment guidelines, are expected in 2015.
Corticosteroids
Corticosteroid treatment is associated with improved survival in 
HIV-uninfected patients with TBM and is recommended in all 
affected patients, regardless of HIV status.[11] In an RCT of adjunctive 
dexamethasone in TBM, this medication was associated with a 
reduced risk of death compared with placebo, which was significant 
in all patients at 9-month follow-up (relative risk: 0.69; p=0.01),[12] but 
only a trend for mortality benefit with dexamethasone was observed 
in subgroup analysis of HIV-infected patients (p=0.08). Of note, 
corticosteroid treatment was associated with a decrease in severe 
adverse events, in particular hepatitis (0/274 v. 8/271 cases in the 
placebo group; p=0.004).
Treatment of HIV infection in TBM patients
A large proportion of HIV-infected patients are antiretroviral therapy 
(ART)-naive or have defaulted ART at TBM presentation. Starting 
ART during TB treatment improves outcome in HIV/TB co-infected 
patients, and one large RCT from Vietnam has provided guidance on 
the timing of ART in such patients.[13] In this study of patients with 
HIV-associated TBM, there was no difference in 9-month mortality 
between severely immunosuppressed TBM patients (median CD4+ 
count = 41  cells/µL) who started ART immediately (within 7 days of 
TB treatment) and those who started later (2 months after TB treatment 
initiation). Grade 4 adverse events were significantly more frequent in 
the ART group who started treatment immediately (80 v. 69%; p=0.04), 
suggesting that delayed treatment may be preferable. In view of these 
findings and the risk of CNS TB-IRIS, current SA DoH ART guidelines 
recommend starting ART 4 - 6 weeks after TB treatment in TBM 
patients, regardless of CD4+ count.
Paradoxical TBM-IRIS
TB-IRIS occurs owing to an exaggerated immune response against TB 
antigens in HIV-infected patients after ART initiation. Paradoxical 
TB-IRIS occurs in patients who typically show clinical improvement 
after starting appropriate TB treatment, and subsequently present with 
new, recurrent or worsening TB symptoms after ART initiation in the 
context of a recovering immune system. Neurological TB-IRIS is the 
most life-threatening form of TB-IRIS, with an associated mortality of 
13 - 75%. Neurological IRIS may present as meningitis, intracerebral 
tuberculoma(s), tuberculous brain abscess, radiculomyelitis or 
spinal epidural abscess. Patients frequently present with atypical 
inflammatory features such as focal meningeal enhancement on brain 
imaging (Fig. 2). In an observational study from Cape Town, 47% of 
TBM patients developed TBM-IRIS at a median of 14 days after ART 
initiation, while mortality due to TBM-IRIS was 12.5% (2/16).[14] 
Table 1. Infective causes and their investigation in the differential diagnosis of patients with suspected HIV-associated tuberculous 
meningitis and/or intracerebral tuberculoma
Differential diagnosis Investigation(s)*
Meningitis
Cryptococcal meningitis India ink, cryptococcal antigen testing, fungal culture
Bacterial meningitis Gram stain, bacterial culture
Non-opportunistic viral meningitis (e.g. Enterovirus) Viral PCR
Neurosyphilis VDRL and TPHA or FTA tests
Herpesvirus meningoencephalitis (e.g. HSV, HZV, CMV, HHV-6) Viral PCR
Lymphomatous meningitis Cytology (and EBV PCR)
HIV seroconversion Serum p24 antigen and conversion of antibody tests
Chronic HIV infection Exclusion of other causes
Non-tuberculous mycobacteria (e.g. MAC) Mycobacterial culture
Intracerebral space-occupying lesion(s)† 
Toxoplasmosis Serum and CSF IgG 
Primary CNS lymphoma Brain biopsy (and EBV PCR)
Bacterial brain abscess Brain biopsy
Cryptococcoma India ink, cryptococcal antigen testing, fungal culture 
Neurosyphilis (gumma) VDRL and TPHA or FTA
PML-IRIS JC virus PCR
PCR = polymerase chain reaction; VDRL = venereal disease research laboratory; TPHA = Treponema pallidum haemagglutination; FTA = fluorescent tryponemal antibody; 
HSV = herpes simplex virus; HZV = herpes zoster virus; CMV = cytomegalovirus; HHV-6 =  human herpesvirus-6; EBV = Epstein-Barr virus; MAC = Mycobacterium avium complex; 
IgG = immunoglobulin G; CNS = central nervous system; PML-IRIS =  progressive multifocal leucoencephalopathy immune reconstitution inflammatory syndrome; JC = John Cunningham.
*Performed on cerebrospinal fluid (CSF), unless otherwise specified.
†In addition to suggested investigations, brain biopsy may be indicated where diagnostic uncertainty persists.
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Factors at TBM presentation associated with subsequent TBM-IRIS 
included high CSF neutrophil count and high CSF bacillary load 
(reflected by M. tuberculosis culture positivity). 
Corticosteroids are the only evidence-based treatment currently 
available for TB-IRIS. In an RCT of prednisone for the treatment 
of non-life-threatening paradoxical TB-IRIS, significant benefit 
was demonstrated with prednisone compared with placebo. 
The combined endpoint was days hospitalised and outpatient 
therapeutic procedures. Additionally, there was also significant 
symptomatic improvement associated with prednisone.[15] Based 
on these findings and anecdotal evidence of the benefit of 
corticosteroids in neurological TB-IRIS, our practice is to treat all 
patients with neurological TB-IRIS with prednisone 1.5 mg/kg/d 
orally (or IV dexamethasone) for at least 2 weeks, after which the 
dose is reduced gradually according to clinical response. Temporary 
interruption of ART should only be considered in patients with a 
severe or persistently depressed level of consciousness and in those 
with severe neurological disability unresponsive to corticosteroid 
therapy.[16] A vital component of the management of HIV-associated 
TBM patients who will start ART is a comprehensive discussion 
with the patient, and preferably also with a family member, about 
the risk of developing neurological TB-IRIS, the typical symptoms 
that could be expected and the need to return to hospital should 
any of these develop.
Conclusion
Owing to a lack of rapid, sensitive diagnostic methods, the diagnosis 
of TBM relies strongly on suggestive clinical, laboratory and imaging 
features and the exclusion of common differential diagnoses. The 
optimal TBM treatment regimen remains to be defined and results 
of ongoing RCTs exploring different treatment options are eagerly 
awaited. Neurological TB-IRIS is a life-threatening complication in 
HIV-associated TBM that should be anticipated in patients who start 
ART during TB treatment.
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